Glioma-Targeted Therapeutics: Computer-Aided Drug Design Prospective

Amongst the several types of brain cancers known to humankind, glioma is one of the most severe and life-threatening types of cancer, comprising 40% of all primary brain tumors. Recent reports have shown the incident rate of gliomas to be 6 per 100,000 individuals per year globally. Despite the vari...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:The Protein Journal Ročník 40; číslo 5; s. 601 - 655
Hlavní autoři: Poonan, Preantha, Agoni, Clement, Ibrahim, Mahmoud A. A., Soliman, Mahmoud E. S.
Médium: Journal Article
Jazyk:angličtina
Vydáno: New York Springer US 01.10.2021
Springer
Springer Nature B.V
Témata:
Animal Anatomy
Antineoplastic Agents - chemistry
Antineoplastic Agents - therapeutic use
Biochemistry
Bioorganic Chemistry
Brain
Brain cancer
Brain Neoplasms - drug therapy
Brain Neoplasms - genetics
Brain Neoplasms - metabolism
Brain tumors
CAD
Cancer
Chemical compounds
Chemistry
Chemistry and Materials Science
Chemotherapy
Computational neuroscience
Computer aided design
Design
Drug Design
Drug development
Drug Discovery
Drug therapy
Glioma
Glioma - drug therapy
Glioma - genetics
Glioma - metabolism
Health aspects
Histology
Humans
Morphology
Organic Chemistry
Patients
Pharmacology
Survival
Temozolomide
Therapeutic targets
Glioma treatment
Computer-aided drug design
Small molecule inhibitors
Therapeutic targets
ISSN:1572-3887, 1875-8355, 1573-4943, 1875-8355
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Amongst the several types of brain cancers known to humankind, glioma is one of the most severe and life-threatening types of cancer, comprising 40% of all primary brain tumors. Recent reports have shown the incident rate of gliomas to be 6 per 100,000 individuals per year globally. Despite the various therapeutics used in the treatment of glioma, patient survival rate remains at a median of 15 months after undergoing first-line treatment including surgery, radiation, and chemotherapy with Temozolomide. As such, the discovery of newer and more effective therapeutic agents is imperative for patient survival rate. The advent of computer-aided drug design in the development of drug discovery has emerged as a powerful means to ascertain potential hit compounds with distinctively high therapeutic effectiveness against glioma. This review encompasses the recent advances of bio-computational in-silico modeling that have elicited the discovery of small molecule inhibitors and/or drugs against various therapeutic targets in glioma. The relevant information provided in this report will assist researchers, especially in the drug design domains, to develop more effective therapeutics against this global disease.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1572-3887
1875-8355
1573-4943
1875-8355
DOI:10.1007/s10930-021-10021-w